Antidopaminergic medications in Huntington's disease
Journal of Huntington's Disease · 2025-02 · 14 (1) · 16-29
DOI: 10.1177/18796397241304312 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Huntington's Disease, online erschienen am 12.01.2025. Verfasst von Andrew M Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Prilenia Therapeutics B.V., Naarden, The Netherlands. Hauptthemen laut MEDLINE: Huntington Disease, Antipsychotic Agents, Dopamine Antagonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Abstract (Originalsprache)
Huntington's disease (HD) is a progressive neurodegenerative disorder marked by motor, cognitive, and behavioral impairments. Antidopaminergic medications (ADMs), such as VMAT2 inhibitors and antipsychotics, are commonly used to manage HD motor disturbances and behavioral disorders. For patients and caregivers, ADMs are an important tool for managing symptoms that negatively affect daily life. However, the impact of ADM use in HD is not firmly understood due to a lack of robust, systematic studies that assessed their overall effect on HD disease. A mounting body of evidence suggests these medications may be associated with worse clinical measures of cognitive function and functional impairment. While regulatory guidelines highlight adverse effects like sedation, cognitive dysfunction, and extrapyramidal symptoms, it is unclear whether ADMs directly impact disease progression or if the side effects mimic or exacerbate measures of HD symptoms in clinical trials. Given ADM effects on the central nervous system and biological uncertainty within HD outcomes, clinical trial designs should recognize the impact of ADMs on key outcomes, as measured by acceptable scales including Total Functional Capacity, Stoop Word Reading, Symbol Digit Modality Test, and the composite Unified Huntington's Disease Rating Scale. The development of novel HD interventions requires consideration of concomitant ADM use that may influence measures of disease presentation. In this review, we highlight the role of ADMs in HD management, their symptomatic benefits and potential risks, especially with high dose associated side effects, interactions with CYP2D6 inhibitors, and the individualized need for careful dose monitoring for clinical care and trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prilenia Therapeutics B.V., Naarden, The Netherlands.
- Department of Neurology, Yale University School of Medicine, New Haven, CT, USA.
- Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
- School of Biosciences Life Sciences Building, Cardiff University Brain Repair Group, Cardiff, UK.
- Advanced Neurotherapeutics Centre, Neuroscience and Mental Health Innovation Institute, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
- Departments of Psychiatry and Medicine, University of British Columbia, Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada.
ORCID-Profile: Andrew M Tan, Karen Anderson
Zitieren
APA
Tan, A. M., Geva, M., Goldberg, Y. P., Schuring, H., Sanson, B. J., Rosser, A., Raymond, L., Reilmann, R., Hayden, M. R., & Anderson, K. (2025). Antidopaminergic medications in Huntington's disease. Journal of Huntington's Disease, 14(1), 16-29. https://doi.org/10.1177/18796397241304312
Vancouver
Tan AM, Geva M, Goldberg YP, Schuring H, Sanson BJ, Rosser A, et al. Antidopaminergic medications in Huntington's disease. Journal of Huntington's Disease. 2025;14(1):16-29. doi:10.1177/18796397241304312
BibTeX
@article{Tan2025,
author = {Tan, Andrew M and Geva, Michal and Goldberg, Y Paul and Schuring, Henk and Sanson, Bernd-Jan and Rosser, Anne and Raymond, Lynn and Reilmann, Ralf and Hayden, Michael R and Anderson, Karen},
title = {Antidopaminergic medications in Huntington's disease},
journal = {Journal of Huntington's Disease},
year = {2025},
volume = {14},
number = {1},
pages = {16--29},
doi = {10.1177/18796397241304312}
}
EUVIMED